Histone demethylase inhibitors

Abstract

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

What is claimed: 
     
         1 . A compound of Formula (I), or pharmaceutically acceptable salt thereof, 
       
         
           
           
               
               
           
         
         wherein,
 X is halogen and n is 0 or 1; 
 Y is —O—, —S—, —SO 2 —, —CF 2 —, —(CH 2 )—N(H)—, —(CH 2 )—N(H)—(C═O)—, or —(CH 2 )—N(C 1 -C 3 alkyl)-(C═O)—; and 
 Z is aryl, carbocyclyl or heterocyclyl. 
 
       
     
     
         2 . The compound of  claim 1 , or pharmaceutically acceptable salt thereof, wherein n is 0. 
     
     
         3 . The compound of  claim 1 , or pharmaceutically acceptable salt thereof, wherein n is 1 and X is fluoro. 
     
     
         4 . The compound of  claim 1 , or pharmaceutically acceptable salt thereof, wherein Y is selected from the group consisting of —O—, —S—, —SO 2 , —CF 2 —, —(CH 2 )N(H)(C═O)— and —(CH 2 )—N(C 1 -C 3 alkyl)-. 
     
     
         5 . The compound of  claim 1 , or pharmaceutically acceptable salt thereof, wherein Z is aryl. 
     
     
         6 . The compound of  claim 5 , or pharmaceutically acceptable salt thereof, wherein Z is phenyl optionally substituted with halogen, alkyl, alkoxy or carbocyclyl. 
     
     
         7 . The compound of  claim 1 , or pharmaceutically acceptable salt thereof, wherein Z is carbocyclyl. 
     
     
         8 . The compound of  claim 7 , or pharmaceutically acceptable salt thereof, wherein Z is 1,2,3,4-tetrahydronaphthalenyl. 
     
     
         9 . The compound of  claim 1 , or pharmaceutically acceptable salt thereof, wherein Z is heterocyclyl. 
     
     
         10 . The compound of  claim 9 , or pharmaceutically acceptable salt thereof, wherein Z is chromanyl. 
     
     
         11 . A pharmaceutical composition comprising the compound of  claim 1 , or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient. 
     
     
         12 . A method of treating a histone demethylase-associated esophageal and breast cancer in a subject comprising administering to said subject a therapeutically effective dose of a compound of  claim 1  or a pharmaceutically acceptable salt thereof. 
     
     
         13 . A method of inhibiting a histone demethylase enzyme comprising contacting the histone demethylase enzyme with a compound of  claim 1 .